FDA
Cefepime Hydrochloride
The FDA lists this product in 19 strengths and forms.
Indications
Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms:
- Pneumonia. ( 1.1 )
- Empiric therapy for febrile neutropenic patients. ( 1.2 )
- Uncomplicated and complicated urinary tract infections (including pyelonephritis). ( 1.3 )
- Uncomplicated skin and skin structure infections. ( 1.4 )
- Complicated intra-abdominal infections (used in combination with metronidazole) in adults. ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 )
1.1 Pneumonia Cefepime for Injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species.
1.2Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection
as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14.1) ].
1.3Uncomplicated and Complicated Urinary Tract Infections
(including pyelonephritis) Cefepime for Injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria.
1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes .
At a glance
- Brand name
- Cefepime Hydrochloride
- Route
- Injection
- Dosage form
- Injectable
- Applicant
- Qilu Antibiotics
- Status
- Prescription
- FDA approval
- 1 Feb 2016
- Application
- ANDA203704-001



